Allakos Inc. (ALLK)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:43AM EDT. Market open.
| Previous close | 1.0100 |
| Open | 1.0300 |
| Bid | 0.7344 x 200 |
| Ask | 1.0100 x 100 |
| Day's range | 0.9900 - 1.0300 |
| 52-week range | 0.9800 - 5.6400 |
| Volume | |
| Avg. volume | 740,445 |
| Market cap | 88.686M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1400 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.90 |
ZacksAllakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- GuruFocus.com
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development Focus
GlobeNewswireAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and continued dosing in the multiple ascending dose (MAD) cohorts of the r
© 2024 Yahoo. All rights reserved.